Phosphorus levels in children treated with intravenous ferric carboxymaltose.
作者信息
Kirk Susan E, Scheurer Michael E, Bernhardt Melanie Brooke, Mahoney Donald H, Powers Jacquelyn M
机构信息
Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer and Hematology Centers, Houston, Texas.
出版信息
Am J Hematol. 2021 Jun 1;96(6):E215-E218. doi: 10.1002/ajh.26165. Epub 2021 Apr 7.
Abstract
摘要
相似文献
1
Phosphorus levels in children treated with intravenous ferric carboxymaltose.接受静脉注射羧基麦芽糖铁治疗的儿童的磷水平
Am J Hematol. 2021 Jun 1;96(6):E215-E218. doi: 10.1002/ajh.26165. Epub 2021 Apr 7.
2
High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.高剂量羧基麦芽糖铁用于射血分数降低的心力衰竭患者时会导致明显的低磷血症。
J Am Coll Cardiol. 2018 May 15;71(19):2270-2271. doi: 10.1016/j.jacc.2018.03.448.
3
Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.铁羧基麦芽糖治疗炎症性肠病儿童缺铁性贫血：疗效和低磷血症风险。
Dig Liver Dis. 2021 Jul;53(7):830-834. doi: 10.1016/j.dld.2021.02.017. Epub 2021 Mar 26.
4
[Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].[低磷血症，静脉使用铁剂鲜为人知的不良反应]
Med Clin (Barc). 2014 Sep 15;143(6):284-5. doi: 10.1016/j.medcli.2013.11.030. Epub 2014 Jan 22.
5
Case report: A rare cause of severe hypophosphatemia.病例报告：严重低磷血症的罕见病因。
Ann Endocrinol (Paris). 2020 Jun;81(2-3):125-126. doi: 10.1016/j.ando.2020.04.008. Epub 2020 May 4.
6
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.铁异麦芽糖苷与羧基麦芽糖铁治疗缺铁性贫血低磷血症的效果：两项随机临床试验。
JAMA. 2020 Feb 4;323(5):432-443. doi: 10.1001/jama.2019.22450.
7
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.铁羧基麦芽糖铁或葡萄糖酸亚铁治疗炎症性肠病患者的低磷血症发生率。
Aliment Pharmacol Ther. 2019 Aug;50(4):397-406. doi: 10.1111/apt.15386. Epub 2019 Jul 2.
8
Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.心力衰竭合并左心室功能不全患者静脉注射羧基麦芽糖铁治疗的疗效、安全性及预后获益
Int J Cardiol. 2016 Jan 1;202:118-20. doi: 10.1016/j.ijcard.2015.08.204. Epub 2015 Sep 1.
9
Hypophosphatemia in children treated with ferric carboxymaltose.接受羧基麦芽糖铁治疗的儿童中的低磷血症。
Acta Paediatr. 2020 Jul;109(7):1491-1492. doi: 10.1111/apa.15178. Epub 2020 Jan 28.
10
[Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].缺铁性贫血患者静脉注射羧麦芽糖铁相关的低磷血症。一种常见的副作用
Med Clin (Barc). 2015 Aug 7;145(3):108-11. doi: 10.1016/j.medcli.2014.10.016. Epub 2015 Jan 8.
引用本文的文献
1
Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement.评估羧基麦芽糖铁导致低磷血症的风险及推荐的管理方法：一项共识声明。
J Clin Med. 2025 Jul 9;14(14):4861. doi: 10.3390/jcm14144861.
2
Ferric carboxymaltose use in pediatric kidney transplant recipients with iron deficiency.羧基麦芽糖铁在缺铁性小儿肾移植受者中的应用。
Pediatr Nephrol. 2025 Jul 26. doi: 10.1007/s00467-025-06869-0.
3
Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.小儿溃疡性结肠炎的管理，第1部分：门诊护理——欧洲儿科胃肠病学、肝病学和营养学会以及欧洲克罗恩病和结肠炎组织的循证共识指南更新版
J Pediatr Gastroenterol Nutr. 2025 Sep;81(3):765-815. doi: 10.1002/jpn3.70097. Epub 2025 Jul 18.
4
Bringing iron to the brain for restless legs.为不宁腿综合征向大脑输送铁元素。
Sleep. 2025 Jul 11;48(7). doi: 10.1093/sleep/zsaf128.
5
Intravenous iron therapy in pediatrics: who should get it and when is the right time?儿科静脉铁治疗：谁应该接受治疗，何时是最佳时机？
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):630-635. doi: 10.1182/hematology.2023000496.
6
Severe iron deficiency anemia in the paediatric emergency department: A retrospective study.儿科急诊科的重度缺铁性贫血：一项回顾性研究。
Paediatr Child Health. 2022 Oct 28;28(1):30-36. doi: 10.1093/pch/pxac095. eCollection 2023 Feb.
7
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.高剂量静脉注射铁剂（如羧基麦芽糖铁或去铁胺麦芽糖铁）：获益-风险评估。
Drug Saf. 2022 Oct;45(10):1019-1036. doi: 10.1007/s40264-022-01216-w. Epub 2022 Sep 6.
8
Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review.静脉注射羧基麦芽糖铁治疗儿童和青少年缺铁和缺铁性贫血：综述。
Eur J Pediatr. 2022 Nov;181(11):3781-3793. doi: 10.1007/s00431-022-04582-w. Epub 2022 Sep 2.
9
Safety of Ferric Carboxymaltose in Children: Report of a Case Series from Greece and Review of the Literature.羧基麦芽糖铁在儿童中的安全性：来自希腊的病例系列报告及文献综述
Paediatr Drugs. 2022 Mar;24(2):137-146. doi: 10.1007/s40272-022-00491-5. Epub 2022 Jan 27.
10
Phosphate Concentrations and Modifying Factors in Healthy Children From 12 to 24 Months of Age.健康儿童在 12 至 24 个月时的磷酸盐浓度及其影响因素。
J Clin Endocrinol Metab. 2021 Sep 27;106(10):2865-2875. doi: 10.1210/clinem/dgab495.
本文引用的文献
1
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.铁异麦芽糖苷与羧基麦芽糖铁治疗缺铁性贫血低磷血症的效果：两项随机临床试验。
JAMA. 2020 Feb 4;323(5):432-443. doi: 10.1001/jama.2019.22450.
2
Hypophosphatemia in children treated with ferric carboxymaltose.接受羧基麦芽糖铁治疗的儿童中的低磷血症。
Acta Paediatr. 2020 Jul;109(7):1491-1492. doi: 10.1111/apa.15178. Epub 2020 Jan 28.
3
Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders.磷稳态的分子调控与低磷血症性疾病的精准治疗
Curr Mol Biol Rep. 2019 Jun;5(2):75-85. doi: 10.1007/s40610-019-0118-1. Epub 2019 Feb 9.
4
Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.静脉注射羧麦芽糖铁用于对口服铁剂反应不佳的缺铁性贫血儿童。
J Pediatr. 2017 Jan;180:212-216. doi: 10.1016/j.jpeds.2016.09.053. Epub 2016 Oct 21.
5
Advances in Pediatric Intravenous Iron Therapy.儿科静脉铁剂治疗的进展
Pediatr Blood Cancer. 2016 Jan;63(1):11-6. doi: 10.1002/pbc.25752. Epub 2015 Sep 16.
Zotero 插件